Enterotoxigenic Escherichia coli (ETEC) is the most commonly isolated pathogen responsible for travelers' diarrhea and the cause of up to 650 million cases of pediatric diarrhea per year in the developing world. As a safe alternative to the prophylactic use of antibiotics, a hyperimmune bovine milk antibody product with specific activity against purified colonization factor antigens (CFAs) was developed and evaluated in a human challenge study. Twenty-five healthy adult volunteers were challenged orally with 10 9 cfu of a virulent CFA/I-bearing ETEC. In the randomized doubleblind trial, 7 of 10 volunteers receiving a lactose-free placebo developed clinical diarrhea after challenge, compared with only 1 of 15 cases in volunteers receiving active product (Fisher's exact test, P õ .0017). It is concluded that antibodies against CFAs alone are sufficient for protection and that prophylaxis with milk-derived immunoglobulin is a feasible alternative to existing drug interventions.
Diarrhea is the most commonly reported illness in travelers to trimethoprim-sulfamethoxazole, 63% to tetracycline, and 48% to ampicillin [6] . In the case of bismuth subsalicylate, from industrialized nations to the developing world. In patients long-term intake carries the risk of salicylate intoxication, espein whom a known pathogen has been identified, enterotoxigenic cially among patients taking salicylates for other reasons [5] .
Escherichia coli (ETEC) is commonly responsible for over half
Over the past 2 decades, a growing body of data has emerged of all cases [1] . It is estimated that of the 16 million people supporting an important role for milk-derived antibodies in traveling to these regions annually, 40% -70% contract ETECprotection against gastrointestinal infectious disease in human related diarrhea [1 -3] . In addition, diarrheal disease in the and animal health. Principally, antibodies from bovine colosdeveloping world can account for as much as one-third of all trum have been used in clinical studies of protection against deaths in children £2 years old [4] .
infection with Cryptosporidium parvum [7, 8] , rotavirus [9, Existing medical options for protecting travelers and children 10], Shigella flexneri [11] , Clostridium difficile [12, 13] , and in developing countries from ETEC infection are limited to Vibrio cholerae [14] . Such products have been shown to be bismuth subsalicylate or prophylactic administration of antibiextremely safe and well tolerated. Oral administration of immuotics, such as trimethoprim-sulfamethoxazole or ciprofloxacin noglobulin with specific activity against whole ETEC cells has [5] . Neither of these interventions, however, is an ideal longalso been tested and shown to protect against oral challenge term solution. Preventative antimicrobial use in the context of with a homologous ETEC strain [15] . world travel could increase greatly the outgrowth of antimicroUnfortunately, the lack of defined protective antigens and bial-resistant pathogens into areas where these drugs are greatly methods for producing large quantities needed for bovine imneeded therapeutically [3] . In fact, data from the Persian Gulf munization have stalled efforts to develop an effective, broadWar reveal a striking number of resistant strains already in spectrum product. In addition, all preparations tested to date existence. Of 125 E. coli strains isolated, 39% were resistant have been made from colostrum, the IgG-rich first postparturition milkings. Purifying antibody from milk could be more economic in large-scale production than using colostrum. To overcome these obstacles, we have developed methods for JID 1998;177 (March) Anti-CFA Milk Immunoglobulin vs. Human ETEC ster, PA). The centrifugation supernatant was collected and conMethods centrated to Ç10% solids using the hollow-fiber filtration system. Bacterial strains for vaccine production. All ETEC strains During this concentrating, residual lactose, milk peptides, and other used in the manufacture of this product were obtained from the salts were removed by step-wise diafiltration against 3 vol of 15 culture collection of the Center for Vaccine Development (UnivermM potassium citrate, pH 6.5. The buffered immunoglobulin fracsity of Maryland, Baltimore). E. coli M424C1 (CS1, CS3) and tion was frozen and subsequently contract-lyophilized (Oregon E9034A (CS3) were used for production of CS1 and CS3; E. coli Freeze Dry, Albany, OR) to produce a stable, dry powder. H10407 was used for production of CFA/I.
Quantitation of anti-CFA activity by ELISA. Anti-CFA titers Production of bovine vaccines. Pure cultures were made from were determined by measurement of binding of milk antibodies frozen vaccine master seed stocks of bacteria maintained at 080ЊC.
to purified antigen-coated plates by ELISA. Ninety-six-well microCrude, CFA-containing, cell-free extracts were obtained by sheartiter plates (Immulon II; Dynatech Laboratories, Chantilly, VA) ing CFAs from the surface of broth-grown cells, followed by cenwere coated with a solution of ú90% pure CFA antigen at 0.5 trifugation. The predominant CFA-containing fraction was partimg/mL overnight at 4ЊC. Coating antigen was removed, and the tioned from the extract by differential ammonium sulfate wells were blocked with 0.1% porcine gelatin in PBS for 1 h at precipitation. The precipitating salt was removed by dialysis 37ЊC. A 10% (wt/vol) aqueous solution of the lyophilized product against 50 mM phosphate buffer, pH 7.2 (Spectra/Por 2, 12-14 was prepared in sterile PBS. Serial 2-fold dilutions were made by kDa cutoff membrane tubing; Spectrum, Laguna Hills, CA). At mixing 50 mL of sample with an equal volume of PBS in microtiter this stage, extracts were monitored for approximate purity and wells. Plated samples were incubated for 1 h at room temperature yield by SDS-PAGE using a 5%-20% polyacrylamide gradient (RT) on a rotating shaker. After a wash with PBS plus 0.1% Tween slab gel and standard buffer conditions [16] . Depending on the 80, a horseradish peroxidase-conjugated goat anti-bovine IgG antigen, CFAs were further purified by either size-exclusion or (Jackson ImmunoResearch Laboratories, West Grove, PA) was ion-exchange chromatography. SDS-PAGE analysis was repeated added at a dilution of 1/100,000 and incubated for 1 h at RT and purity determined by scanning densitometry (model GS300; with shaking. After another wash, H 2 O 2 substrate and chromagen Hoefer Scientific Instruments, San Francisco). Preparations in (3,3,5,5-tetramethylbenzidine-2 HCl) were added. Color develwhich ú70% of all Coomassie brilliant blue staining protein was opment was stopped by addition of 40% H 2 SO 4 , and absorbance CFA were considered acceptable for use as bovine vaccines. The was measured at 450 nm using a kinetic microplate reader. Because CFAs were concentrated, diafiltered, and sterilized by passage the absolute ELISA titer or optical density is variable and depenthrough a 0.45-mm filter. All vaccine preparations were tested for dent primarily on the antigen preparation used to coat the wells, bacterial and fungal sterility and the presence of õ100,000 EU/ the most accurate and meaningful comparison of multiple samples mL endotoxin, as determined by limulus amebocyte lysate assay was made by establishing a reference standard from which all (QCL 1000/LAL; BioWhittaker, Walkersville, MD). The final vacunknown sample titers were interpolated. Dilutions of our anticine was prepared by mixing the appropriate dose of antigen 1:1 CFA milk standard were run on each plate containing unknown (vol/vol) with a synthetic, metabolizable, oil-based adjuvant.
samples, and a standard curve was constructed. Titers for unknown Bovine vaccinations. All vaccinations were performed under samples were then interpolated from the standard curve. This northe direction of a licensed veterinarian. All animals used were malized all ELISA data and permitted meaningful comparisons healthy Holstein dairy cows. Health records were maintained, and between samples run on different assays to be made. only healthy, mastitis-free animals were included in the milk pool.
Comparison of anti-CFA, anti-lipopolysaccharide (LPS), anti-A series of intramuscular vaccinations was administered deep into
heat-labile toxin (LT), and anti-type I pilus-specific activity by the rear thigh muscle. A total volume of 2 mL was administered ELISA. Microtiter plates were divided into four quadrants so that at a single site and the animals were monitored for adverse reaccomparative analyses could be run side-by-side. This minimizes tions. None were observed. Milk was collected regularly beginning error due to plate-to-plate variation. To each quadrant was applied shortly after administration of the final vaccination. Although the a different coating antigen: CFA/I, E. coli LT, E. coli LPS (O78, anti-CFA titers for each batch were known, no attempt was made O127), or type I somatic pilus. CFA/I and LPS O78 were purified to use only the highest titer milk for production. To simulate from challenge strain E. coli H10407, type I somatic pilus was continuous manufacture, milk from seven different batches, colpurified from E. coli strain H10407P, and LPS O127 was obtained lected over a 4-week period, were pooled to make the clinical test commercially (Sigma, St. Louis). Lyophilized product was used material described herein.
to prepare a fresh 10% (wt/vol) solution in microfiltered, deionized Preparation of anti-E. coli bovine milk immunoglobulin. Hywater, serially diluted (1/2000-1/640,000) and subjected to ELISA perimmune milk was processed into cheese by standard dairy pracanalysis by methods described above. tices. The whey fraction (containing the immunoglobulin) was IgG purity. Total protein was determined by the Dumas Classipasteurized and fat was removed by centrifugation. Defatted whey cal Digestion Assay (Association of Official Analytical Chemists was enriched for immunoglobulin by ion-exchange chromatogra-
[AOAC] method). The percentage of total protein that was bovine phy using a continuous contacting, pilot scale, automated chromaIgG was determined by resolving all proteins by SDS-PAGE and tography system (ISEP, model L0604; Advanced Separation Techquantitating IgG by scanning densitometry. Briefly, lyophilized nologies, Lakeland, FL) and concentrated by hollow-fiber filtration product was reconstituted in PBS to an approximate protein con-(model UFP-30-C-75; A/G Technology, Needham, MA) using a centration of 1 mg/mL and mixed 1:1 with standard running buffer. series of four polysulfone filtration cartridges (30,000 molecular Samples (10 mL each) were applied to 5%-20% polyacrylamide weight cutoff). Phospholipids and residual non-immunoglobulin slab gels and electrophoresed using the system of Laemmli [16] . proteins were precipitated chemically and removed by continuousflow centrifugation (model AS-16; Alfa-Laval/Sharples, WarminAfter Coomassie brilliant blue staining, the percentage of total Figure 1 . SDS-PAGE of purified protein that was bovine IgG was determined using an automated CFA/I: Coomassie brilliant bluescanning densitometer.
stained, 5% -20% polyacrylamide Volunteer study. Twenty-five healthy adult volunteers, housed gradient gel showing CFA/I that as in-patients in the isolation ward at the Center for Vaccine Develwas purified from broth cultures of opment (University of Maryland School of Medicine), were ranenterotoxigenic E. coli H10407 domly assigned to 3 groups-placebo (n Å 10), high-dose treat-(O78:H11). Solution (500 mg/mL) ment (n Å 11), and low-dose treatment (n Å 4)-by assigning of antigen in PBS was mixed 1:1 subject identification numbers to identically packaged foil pouches with sample buffer containing 20 containing measured doses of each test article. The randomization mM dithiothreitol and run under list was generated and secured by ImmuCell's Quality Assurance reducing conditions. Prominent band at 15 kDa is CFA/I. This Supervisor. All investigators and volunteers were blinded to these preparation is representative of antreatment group assignments throughout the study and during astigens used in vaccines to inoculate sessment of outcome. Each placebo pouch contained a single dose dairy cattle for production of antiof a lactose-free infant formula (Lactofree;
subset (10, 20, 50 kDa) of these On day 3, 2 h after consuming the morning dose, all volunteers markers shown for reference. drank 4 ounces (120 mL) of water containing 2 g of sodium bicarbonate. One minute later, each received an oral challenge inoculum containing 10 9 cfu of H10407 (O78:H11), a CFA/I-bearAnti-O78 LPS. Serum levels of IgG against O78 LPS were ing ETEC strain suspended in 1 ounce (30 mL) of water containing also determined by ELISA. Plates were coated with 5 mg/mL O78 sodium bicarbonate. Fifteen minutes later, a second dose of either LPS purified from H10407. The assay was carried out as described product or placebo was given. The usual evening dose was adminabove. istered after dinner. On days 4-7, three doses/day were administered, as previously done, after each meal.
Volunteers collected every bowel movement produced during ciprofloxacin (500 mg twice per day) to eradicate the challenge Antigen preparations that were ú70% CFA were incorporated organism.
into the bovine vaccines. tometry and SDS-PAGE (figure 2). Since the powder is 78%
plates for agglutination with anti-O78 and anti-CFA/I serum.
protein, of which 76% is IgG, it is 59% IgG by weight. AddiBlood samples were drawn from volunteers before the study tional milk proteins present include b-lactoglobulin, a-lactalbegan (baseline) and on days 10 and 31 for serology, blood cell bumin, serum albumin, and trace amounts of casein.
counts, and determination of anti-CFA, anti-LT, and anti-LPS re-
Immunologic evaluation of milk antibody product by ELISA.
sponses.
To establish a specific role for anti-CFA antibodies in protecAnti-CFA/I. Serum levels of IgG against CFA/I were determined by ELISA essentially as described for the active product, tion against ETEC challenge, we wished to determine the powith the following modifications. Antigen-coated plates were tency of anti-CFA/I activity in the product relative to activity blocked with PBS containing 0.1% fetal bovine serum instead of against O78 LPS, LT, and type I (somatic) pili. A comparative the 0.1% porcine gelatin used for the product assays, as this was ELISA was performed, and the relative titers of anti-CFA/I, found superior for reducing background. In addition, the reference anti-LPS, anti-LT, and anti -type I pilus activity were deterstandard comprised a pool of human serum from patients in this mined (table 1). As a negative control, side-by-side samples study rather than the hyperimmune milk reference standard used of a commercially available, hyperimmune anti-K99 / bovine to assay the product. ). This preparation is representafree infant formula (see Methods).
Figure 2. SDS-PAGE of anti -E. coli
tive of clinical material that was admin-* 1 liquid stool of §300 mL or 2 liquid stools totaling 200 mL during any istered in study described here. Individ-48-h period within 120 h after challenge.
ual doses of lyophilized powder were † Calculated for combined treatment groups: diarrhea incidence in control dissolved in 150 mL of water containing group (70%) minus diarrhea incidence in combined treatment groups (6.67%) sodium bicarbonate and ingested orally. Clinical. Seven of the 10 volunteers in the placebo group had diarrhea after challenge, compared with only 1 of 15 volunteers in the 2 groups receiving the active product (table 2, was reported by 6 of 10 controls compared with 1 of 15 treated. Fisher's exact test, P õ .0017). In comparing the attack rate Malaise was found in 3 of 10 controls and 1 of 15 treated. in the placebo group (70%) with the attack rate in the treated Five of 10 controls experienced headaches compared with 4 groups (6.7%), prophylactic administration of the hyperimof 15 treated subjects. Finally, while all 10 volunteers receiving mune milk immunoglobulins brought about a protection rate the placebo experienced abdominal cramps, only 2 of 15 volunof Ç90%. The mean stool volume in volunteers with diarrhea teers receiving the product did. No adverse side effects attributwas 1327 mL (range, 263 -4421), and the mean number of able to ingestion of the bovine antibody were observed in any stools was 7.4 (range, 2 -21). The mean incubation time was volunteer. 58.8 h (range, 19.4 -100.3).
Bacteriology. Daily stool samples were analyzed for the Daily medical rounds were conducted to record the incidence presence of the challenge organism to quantitate shedding over of several other symptoms besides diarrhea (table 3) . Anorexia time. The average number of challenge organisms shed by volunteers receiving the placebo at the time of maximal shedding was 4.5 1 10 8 cfu/g of stool. The equivalent mean bacte- mune responses to all three antigens. Second, mean peak serum responses to all three E. coli surface antigens are lower in raised against the three other antigens (table 1). Given that anti-CFA immunity was the predominant anti-ETEC activity both active groups than in the placebo group. The mean peak responses to LT and LPS were 2.7 and 2.5 times lower, respecin the concentrate, these results strongly suggest a central role for CFA-specific antibodies in protection against oral ETEC tively, and the mean peak response to CFA/I was nearly 2-fold lower.
challenge.
As travelers' diarrhea caused by ETEC is primarily a foodborne infection, the dosing schedule utilized in this study was Discussion designed to model ingestion of milk antibodies with or shortly Oral prophylaxis with hyperimmune bovine milk immunoafter meals. The positive results of this trial confirm that proglobulin provided 90% protection against clinical diarrhea phylaxis using this type of dosing schedule can be highly effeccaused by oral challenge with ETEC in a placebo-controlled, tive. Since the initial dose was administered shortly after chalhuman challenge study (Fisher's exact test, P õ .0017). Reduclenge, it is not known whether a less frequent dosing regimen tion in concomitant disease symptomology and microbial stool would be equally efficacious. counts were also observed. In addition, there were no adverse Microbiologic analyses revealed that although all volunteers events due to ingestion of the milk antibodies.
shed high numbers of challenge organisms in their stool, the Although prevention of ETEC infection with oral milk antimean peak number of challenge organisms shed by individuals bodies has been demonstrated before [15] , identification of the in the placebo group (4.5 1 10 8 /g of stool) was Ç1 log higher molecular target of protective immunity has remained elusive.
than that for the treatment groups (6.2 1 10 7 /g of stool). This Drawing analogies to virulence mechanisms utilized by other difference is not significant, but these data do suggest that enteric pathogens, colonization factors, LPS, LT, and type I eradication of the organism is not the primary mechanism of (somatic) pilus have all been investigated as potential candidate protection. Since ETEC diarrhea occurs when sufficient toxin molecules. The milk antibodies produced here provided a is expressed in close proximity to the intestinal epithelium means of directly testing the relative importance of anti-CFA to cause secretory disease, oral immunoglobulins may confer immunity. By using purified CFAs in place of killed whole protection by effectively reducing the number of organisms cells to immunize donor dairy cattle, the milk produced was that can attach and locally elaborate toxin below the threshold greatly enriched for anti-CFA immunity. Specifically, the antinecessary to cause disease. CFA/I titer was 32 times greater than the comparable titers A central issue relating to practical use of oral passive antibodies is whether such treatments dampen the development of natural immunity. In this study, milk immunoglobulins did 
